SOURCE: TapImmune Inc.

December 06, 2007 09:00 ET

TapImmune Inc. Announces Granting of U.S. Pat. Appln No. 10/046,542 Petition to Revive and Secure Bridge Financing

Patent Portfolio on Track and Funding Secured for Further Development Projects

VANCOUVER, BC--(Marketwire - December 6, 2007) - TapImmune Inc. (OTCBB: TPIM) (the "Company"), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced the USPTO has granted its petition to revive the U.S. Pat. Appln No. 10/046,542.

This is a key patent application for the Company, as it describes a preferable delivery method for the TAP gene sequences and serves as the basis for further expansion of the Company's technology. The Company has engaged substitute United States patent counsel, the firm Rissman, Hendricks, Jobse & Oliverio, of Boston, Massachusetts, which has obtained this revival, and which will now proceed to prepare and submit additional claims with respect to the subject matter disclosed in U.S. Patent Appln No. 10/046,542, including filing further continuations thereto. The Company is effecting a full transfer of its files and pending matters at the U.S. Patent and Trademark Office from its former counsel to replacement counsel.

"We are very pleased to have received a favourable response from the patent office," said Denis Corin, CEO. "This news solidifies our IP portfolio and opens the door for future filings to further strengthen our intellectual property and create value for our shareholders. It also creates a more secure environment from which we can approach potential partners for our technology."

The Company also announced the closing of a bridge financing of $445,000. The cash infusion will see the Company through and into the first half of next year and allow for continued development and manufacturing contracts to be pursued.

About TapImmune Inc.

TapImmune Inc. is a biotechnology Company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidate, in preclinical tests has been shown to restore and augment antigen presentation and subsequent recognition and elimination of cancer cells by the immune system. The Company is preparing the commencement of toxicology studies on AdhTAP leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

Contact Information